DRSLTR 1 filename1.htm DRSLTR
   12670 High Bluff Drive
   San Diego, California 92130
   Tel: +1.858.523.5400 Fax: +1.858.523.5450
   www.lw.com

 

LOGO

  

 

FIRM / AFFILIATE OFFICES

   Beijing    Moscow
   Boston    Munich
   Brussels    New York
   Century City    Orange County
December 17, 2020    Chicago    Paris
   Dubai    Riyadh
   Düsseldorf    San Diego
   Frankfurt    San Francisco
   Hamburg    Seoul
   Hong Kong    Shanghai
   Houston    Silicon Valley
   London    Singapore

CONFIDENTIAL SUBMISSION

VIA EDGAR

   Los Angeles    Tokyo
   Madrid    Washington, D.C.
   Milan   

U.S. Securities and Exchange Commission

Division of Corporate Finance

100 F Street, NE Washington, DC 20549

 

  Re:

Connect Biopharma Holdings Limited

      

Draft Registration Statement on Form F-1

      

Submitted December 17, 2020

Ladies and Gentlemen:

On behalf of Connect Biopharma Holdings Limited, a Cayman Islands exempted company with limited liability (the “Company”), we hereby confidentially submit a draft Registration Statement on Form F-1 (the “Registration Statement”) of the Company as an “Emerging Growth Company” pursuant to Title I, Section 106 under the Jumpstart Our Business Startups Act of 2012 and Section 24(b)(2) of the Securities Exchange Act of 1934 for non-public review by the Staff of the U.S. Securities and Exchange Commission (the “Staff”) prior to the public filing of the Registration Statement.

Pursuant to the applicable provisions of the Fixing America’s Surface Transportation Act and based on guidance issued by the Staff in connection therewith, the Company is omitting from the Registration Statement (i) its interim consolidated financial statements as of and for the nine months ended September 30, 2019 and 2020 and (ii) pro forma and pro forma loss per share information for the years ended December 31, 2018 and 2019, because they relate to historical periods that we believe will not be required to be included in the Registration Statement at the time we first file this Registration Statement publicly.

*********

If you have any questions with respect to this confidential submission, please call me at 858-523-3959.


December 17, 2020

Page 2

 

LOGO

 

Very truly yours,
/s/ Michael E. Sullivan

Michael E. Sullivan

of LATHAM & WATKINS LLP

 

cc:

Zheng Wei, Ph.D., Connect Biopharma Holdings Limited

    

Wubin Pan, Ph.D., Connect Biopharma Holdings Limited

    

Jeffrey T. Woodley, Latham & Watkins LLP